König, Fatima Barbara

[["dc.bibliographiccitation.firstpage","660"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Archives of Orthopaedic and Trauma Surgery"],["dc.bibliographiccitation.lastpage","669"],["dc.bibliographiccitation.volume","125"],["dc.contributor.author","Ernstberger, Thorsten"],["dc.contributor.author","Kogel, M."],["dc.contributor.author","Konig, F."],["dc.contributor.author","Schultz, Wolfgang"],["dc.date.accessioned","2018-11-07T10:53:41Z"],["dc.date.available","2018-11-07T10:53:41Z"],["dc.date.issued","2005"],["dc.description.abstract","Introduction: The objectives of surgical interventions for tumoral lesions of the spine include the establishment and improvement of tumor-related symptoms. Anterior tumor resection followed by reconstruction indicated if surgical treatment allowed a marginal removal of the tumor or could extend the individual survival rate in combination with adjuvant therapy options. Sufficient re-stabilization depends on adequate anterior column reconstruction. The purpose of this retrospective study was to present our experiences and results after anterior tumor resection followed by reconstruction with the expandable vertebral body replacement device (VBR, Ulrich, Germany) based on clinical application over 4 degrees years. Patients and methods: We carried out an anterior tumor resection followed by reconstruction using an anterior extendable device in 32 patients with different spine tumors between 1996 and 2000. A retrospective evaluation was executed considering the patients medical records and radiological findings. Additionally, a clinical and radiological investigation of still living postoperative patients was carried out. Results: The mean surgical time of all evaluated patients was 317.2 min. The average blood loss was 1,272.5 ml. According to the Tokuhashi score, patients with a postoperative survival time of at least 12 months demonstrated a score value >= 9 points. According to our evaluated patients group metastatic lesions of the spine represented the largest group (78.1%). The average survival rate of this group amounted to 18.4 months postoperatively. Considering primary tumors the average survival rate at the time of last re-examination amounted to 34.8 months postoperatively. Preoperative neurological pathologies were present in 12 patients (Frankel stage C-D). During the postoperative monitoring period 58.3% of the patients demonstrated an improvement in initial neurological findings. There were no intraoperative complications or perioperative deaths. Implant dislocations were not observed. Conclusion: On account of the underlying, the anterior tumor resection with supplementary instrumentation represented a sufficient procedure in spinal tumor surgery. Adjuvant therapy can influence the postoperative survival period positively in addition to the surgical procedure. Following anterior tumor resection, extendable vertebral body replacements like the VBR device provide immediate spine stability by excellent defect adaptation. With regard to their intraoperative flexibility, expandable cages are more advantageous in contrast to non-expandable implants or bone grafts."],["dc.identifier.doi","10.1007/s00402-005-0057-6"],["dc.identifier.isi","000233484500002"],["dc.identifier.pmid","16215720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49402"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0936-8051"],["dc.title","Expandable vertebral body replacement in patients with thoracolumbar spine tumors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1742"],["dc.bibliographiccitation.issue","20"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","1744"],["dc.bibliographiccitation.volume","68"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Rudofsky, G., Jr."],["dc.contributor.author","Kress, B."],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Konig, F."],["dc.contributor.author","Schwenger, V."],["dc.date.accessioned","2018-11-07T11:02:23Z"],["dc.date.available","2018-11-07T11:02:23Z"],["dc.date.issued","2007"],["dc.identifier.doi","10.1212/01.wnl.0000260226.21010.2b"],["dc.identifier.isi","000246450500019"],["dc.identifier.pmid","17360963"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51372"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0028-3878"],["dc.title","The tumor necrosis factor-associated periodic syndrome, the brain, and tumor necrosis factor-A antagonists"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","9"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Molecular and Cellular Endocrinology"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","200"],["dc.contributor.author","Tascou, S."],["dc.contributor.author","Trappe, Ralf"],["dc.contributor.author","Nayernia, K."],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Konig, F."],["dc.contributor.author","Schulz-Schaeffer, Walter J."],["dc.contributor.author","Saeger, W."],["dc.contributor.author","Meinhardt, Andreas"],["dc.contributor.author","Engel, Wolfgang"],["dc.contributor.author","Schmidtke, Joerg"],["dc.contributor.author","Burfeind, Peter"],["dc.date.accessioned","2018-11-07T10:40:52Z"],["dc.date.available","2018-11-07T10:40:52Z"],["dc.date.issued","2003"],["dc.description.abstract","In an attempt to determine the susceptibility of spermatogonia to malignant transformation transgenic mice were generated harboring a 1.3 kb 5'-flanking region of the germ cell specific expressed human testis specific protein, Y-encoded gene fused with the simian virus 40 large T antigen (TAg). Unexpectedly, TAg expression in transgenic mice was also detected in somatic tissues. Between days 65 and 85 after birth most of the transgenic mice developed anterior lobe tumors of the pituitary gland and to a less extent medulla type tumors of the adrenal gland. In addition, a few older transgenic mice developed tumors of the seminal vesicle, but no testicular tumors were observed in transgenic mice up to an age of 5 months. The pituitary tumors were immunoreactive for anti-prolactin (PRL) and anti-adrenocorticotropic hormone (ACTH). PRL and corticosterone concentrations in serum of transgenic mice were significantly increased. Taken together, our studies provide a novel mouse model for pituitary adenomas displaying a unique combination of hormone expression by tumor cells secreting PRL and ACTH. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0303-7207(02)00426-4"],["dc.identifier.isi","000181913300002"],["dc.identifier.pmid","12644295"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46406"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ireland Ltd"],["dc.relation.issn","0303-7207"],["dc.title","TSPY-LTA transgenic mice develop endocrine tumors of the pituitary and adrenal gland"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.volume","253"],["dc.contributor.author","Lindquist, S."],["dc.contributor.author","Bodammer, N."],["dc.contributor.author","Kaufmann, J."],["dc.contributor.author","Konig, F."],["dc.contributor.author","Heinze, Hans-Jochen"],["dc.contributor.author","Bruck, Wolfgang W."],["dc.contributor.author","Sailer, M."],["dc.date.accessioned","2018-11-07T09:53:42Z"],["dc.date.available","2018-11-07T09:53:42Z"],["dc.date.issued","2006"],["dc.format.extent","124"],["dc.identifier.isi","000238478600474"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36380"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.publisher.place","Darmstadt"],["dc.relation.conference","16th Annual Meeting of the European-Neurological-Society"],["dc.relation.eventlocation","Lausanne, SWITZERLAND"],["dc.relation.issn","0340-5354"],["dc.title","Balo's concentric sclerosis: multimodal MRI reveals dynamics of different pathophysiological processes"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","7"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","16"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Pittock, Sean J."],["dc.contributor.author","Reindl, Markus"],["dc.contributor.author","Achenboch, S."],["dc.contributor.author","Berger, T."],["dc.contributor.author","Bruck, Wolfgang W."],["dc.contributor.author","Konig, F."],["dc.contributor.author","Morales, Y."],["dc.contributor.author","Lassmann, Hans"],["dc.contributor.author","Bryants, S."],["dc.contributor.author","Moore, S. B."],["dc.contributor.author","Keegan, B. M."],["dc.contributor.author","Lucchinetti, Claudia F."],["dc.date.accessioned","2018-11-07T11:07:09Z"],["dc.date.available","2018-11-07T11:07:09Z"],["dc.date.issued","2007"],["dc.description.abstract","Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzyme-linked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2-genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern 1, 43 pattern 11 and 17 pattern Ill. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa = 0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus."],["dc.description.sponsorship","NCRR NIH HHS [M01 RR00585]"],["dc.identifier.doi","10.1177/1352458506072189"],["dc.identifier.isi","000243823800001"],["dc.identifier.pmid","17294606"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12982"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52483"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.relation.issn","1352-4585"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","430"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","438"],["dc.bibliographiccitation.volume","77"],["dc.contributor.author","Schilling, S."],["dc.contributor.author","Linker, R. A."],["dc.contributor.author","König, F. B."],["dc.contributor.author","Koziolek, M."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Müller, G. A."],["dc.contributor.author","Paulus, W."],["dc.contributor.author","Gärtner, J."],["dc.contributor.author","Brück, W."],["dc.contributor.author","Chan, A."],["dc.contributor.author","Gold, R."],["dc.date.accessioned","2017-09-07T11:53:08Z"],["dc.date.available","2017-09-07T11:53:08Z"],["dc.date.issued","2006"],["dc.description.abstract","Patients with severe multiple sclerosis (MS) relapses which do not respond sufficiently to corticosteroids can undergo escalating immunotherapy with plasma exchange. We review the course of 14 apheresis cycles in 13 adult patients and three pediatric cases from our center between 2004 and 2005. Nine cases were due to optic neuritis, five had experienced clinically isolated syndromes, and two suffered from Devic's disease. Of the adult patients, 71% had good or very good outcome. The mean time point of improvement was after the third plasmapheresis session, and early initiation of plasma exchange therapy (within 1 month after begin of relapse) was associated with better outcome. In pediatric MS, two of three patients showed clear improvement. These data argue for a very good therapeutic effect of plasma exchange if performed early and with adequate indication."],["dc.identifier.doi","10.1007/s00115-005-2019-1"],["dc.identifier.gro","3143715"],["dc.identifier.isi","000237631700004"],["dc.identifier.pmid","16341736"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1260"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0028-2804"],["dc.title","Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses. Clinical experience with 16 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","329"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Knee Surgery Sports Traumatology Arthroscopy"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Koulalis, D."],["dc.contributor.author","Schultz, Wolfgang"],["dc.contributor.author","Heyden, Mariano L. M."],["dc.contributor.author","Konig, F."],["dc.date.accessioned","2018-11-07T10:47:46Z"],["dc.date.available","2018-11-07T10:47:46Z"],["dc.date.issued","2004"],["dc.description.abstract","Autologous osteochondral grafting (mosaicplasty) was performed on 18 patients with grade IV cartilage defects of the knee joint. The average age of these 12 men and 6 women was 36 years, follow-up time was 27.2 months and defect size was 252 mm(2) (18x14mm). After plain anteroposterior and lateral radiographs and MRI (STIR sequence) examination, diagnostic arthroscopy was performed, followed by autologous osteochondral grafting, avoidance of weight bearing for 6-8 weeks, physiotherapy and continuous passive motion. All patients showed, radiologically (MRI), a full coverage of the defect with articular surface congruity postoperatively. The postoperative ICRS score was normal for 12 and nearly normal for 6 patients. Seven patients showed early persistent joint effusion for an average of 5.3 months. Hyaline-like cartilage coverage was found in four patients on second-look arthroscopy. The transplantation of autologous osteochondral grafts is being applied in an effort to reconstruct the affected articular surface with properties similar to those of hyaline cartilage. This method retains the integrity and function of a damaged joint, providing promising results in terms of preventing the development of early arthritis in young patients."],["dc.identifier.doi","10.1007/s00167-003-0392-5"],["dc.identifier.isi","000223310400013"],["dc.identifier.pmid","14513209"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48044"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0942-2056"],["dc.title","Autologous osteochondral grafts in the treatment of cartilage defects of the knee joint"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Urologe"],["dc.bibliographiccitation.lastpage","64"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","König, F."],["dc.contributor.author","Strauß, A."],["dc.contributor.author","Johannsen, M."],["dc.contributor.author","Mommsen, C."],["dc.contributor.author","Fricke, E."],["dc.contributor.author","Klier, J."],["dc.contributor.author","Mehl, S."],["dc.contributor.author","Pfister, D."],["dc.contributor.author","Sahlmann, C.-O."],["dc.contributor.author","Werner, A."],["dc.contributor.author","Goebell, P. J."],["dc.date.accessioned","2020-12-10T14:08:42Z"],["dc.date.available","2020-12-10T14:08:42Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00120-019-01052-4"],["dc.identifier.eissn","1433-0563"],["dc.identifier.issn","0340-2592"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70520"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Radium-223 zur Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC)"],["dc.title.alternative","Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The androgen receptor-independent active agent in the therapeutic sequence"],["dc.title.subtitle","Der androgenrezeptorunabhängige Wirkstoff in der therapeutischen Sequenz"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2101"],["dc.bibliographiccitation.issue","3A"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","2105"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Korabiowska, M."],["dc.contributor.author","Voltmann, J."],["dc.contributor.author","Honig, J. F."],["dc.contributor.author","Bortkiewicz, P."],["dc.contributor.author","Konig, F."],["dc.contributor.author","Cordon-Cardo, C."],["dc.contributor.author","Jenckel, F."],["dc.contributor.author","Ambrosch, Petra"],["dc.contributor.author","Fischer, G."],["dc.date.accessioned","2018-11-07T09:50:44Z"],["dc.date.available","2018-11-07T09:50:44Z"],["dc.date.issued","2006"],["dc.description.abstract","The relevance of double-strand DNA repair genes has been demonstrated in several tumours. The main aim of this study was to analyse the expression of the heterodimers Ku70 and Ku80, building regulatory subunits of the DNA-dependent protein kinase in 40 oral carcinomas. Ku70 expression was found in 87.5% of grade 1 and grade 3 tumours and in 82.9% of grade 2 carcinomas. Ku80 presence was noted in 87.5% of grade 1 tumours, 82.9% of grade 2 tumours and in all grade 3 tumours. Ku70-positive cells were present in 90.5% of tumours without and in 80% of tumours with lymphatic metastases. A similar relationship was found for Ku80 expression. Additionally, the expression of Ku70 was highly significantly related to smoking habits. Our results demonstrated that defects of DNA double-strand repair genes play an important role in the tumour progression of oral carcinomas."],["dc.identifier.isi","000238490700052"],["dc.identifier.pmid","16827151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35768"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Int Inst Anticancer Research"],["dc.relation.issn","0250-7005"],["dc.title","Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7032"],["dc.bibliographiccitation.journal","MULTIPLE SCLEROSIS"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Kantarci, O. H."],["dc.contributor.author","Ziemer, P."],["dc.contributor.author","Konig, F."],["dc.contributor.author","Bruck, Wolfgang W."],["dc.contributor.author","Lassmann, Hans"],["dc.contributor.author","Lucchinetti, Claudia F."],["dc.date.accessioned","2018-11-07T10:46:07Z"],["dc.date.available","2018-11-07T10:46:07Z"],["dc.date.issued","2004"],["dc.format.extent","S154"],["dc.identifier.isi","000225459800202"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47671"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Arnold, Hodder Headline Plc"],["dc.publisher.place","London"],["dc.relation.conference","20th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple- Sclerosis/9th Annual Meeting of Rehabilitation in MS"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","1352-4585"],["dc.title","Gender differences in immunopathological patterns of multiple sclerosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]